APOGEPHA Arzneimittel GmbH
APOGEPHA is an independent, German, medium-sized pharmaceutical company specialising in the field of urology, with its own production facilities. We developed propiverine, one of the leading medicines for the treatment of overactive bladder and neurogenic detrusor overactivity in adults and children.
Various dosages and formulations of propiverine are available under the trademarks Mictonorm® and Detrunorm®.
The patent of our unique once daily formulation of propiverine is approved in most countries. Currently we have marketing and distribution partners in more than twenty countries, with a focus on Europe and Asia.
We are looking for out-licensing partners with expertise in the urology sector in all promising markets.